Crossmark

Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort

Crossref DOI link: https://doi.org/10.1007/s12471-025-01941-8

Published Online: 2025-03-06

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deiman, Frederik E.

de Brouwer, Remco

Baumhove, Lukas

Bomer, Nils

Grote Beverborg, Niels

van der Meer, Peter
Funding

Funding for this research was provided by:

AstraZeneca Mölndal
License Information

Text and Data Mining valid from 2025-03-06

Version of Record valid from 2025-03-06
More Information

Article History

Accepted: 28 January 2025

First Online: 6 March 2025

Conflict of interest

: P. van der Meer has received grants from AstraZeneca, Ionis Pharmaceuticals, Novo Nordisk, Novartis, Pharmacosmos, Vifor Pharma, Pfizer, Pharma Nord and BridgeBio, outside the submitted work. F.E. Deiman, R. de Brouwer, L. Baumhove, N. Bomer and N. Grote Beverborg declare that they have no competing interests.

Document is current

Any future updates will be listed below